Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in male patients with androgenetic alopecia, combining botulinum toxin type A with 5% Minoxidil significantly improved hair growth, patient satisfaction, and quality of life over six months, compared to using Minoxidil alone, without causing adverse effects.

In this randomized controlled trial, researchers are assessing the efficacy and safety of acupoint catgut embedding combined with topical 5% minoxidil in treating androgenetic alopecia among 70 men, with primary outcomes focusing on changes in hair count after 24 weeks of treatment.

This study found that increased dihydrotestosterone levels were observed in both androgenetic alopecia patients and controls, suggesting that follicle sensitivity to DHT may be more critical than DHT levels for alopecia development.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study found that dimethylarsinic acid significantly accelerates skin tumor development in hair follicle-targeted K6/ODC transgenic mice.

This study detailed the implementation of an autonomous AI device in an NHS skin cancer pathway, showing that it achieved a sensitivity of 97.3% for diagnosing skin cancers and exceeded sensitivity targets compared to specialists with a negative predictive value over 99.7%.

This study found that administering dutasteride did not change spermatogenesis or oxidative stress levels in rat testes, though further research is needed to confirm these findings.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study concluded that administering dutasteride for more than 8 weeks in rats could lead to irreversible erectile dysfunction, even after stopping the medication.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

The AUTS2 gene is linked to neurological disorders and may affect human brain development and cognition.

In this case study, a 64-year-old female with breast cancer undergoing ADC therapy experienced significant hair regrowth using oral minoxidil, suggesting its potential as a treatment for ADC-induced alopecia.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

This study identified three EDAR gene variants potentially linked to hypohidrotic ectodermal dysplasia in three Pakistani families, which could aid in genetic counseling for similar cases.

This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

A woman's unique dementia was misdiagnosed, a genetic mutation increases Parkinson's risk with age, and finasteride may help with Tourette syndrome.

In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

A man developed hair loss from testosterone treatment but improved with additional medication.

In this study, researchers observed that after 5 years of treatment, 89.9% of Korean men with androgenetic alopecia experienced improvement and 93.9% had prevention of disease progression with dutasteride 0.5mg, though sexual-related symptoms were common early but subsided over time.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.